Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03678389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 283 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor 8 versions Re-verified since Apr 18, 2026, no change to tracked fieldsv276-v283
  2. Notable Primary endpoint(s) modifiedv275 See this version in full on ClinicalTrials.gov ↗
  3. Minor Re-verified, no change to tracked fieldsv274
  4. Minor Study description expanded, about 212 wordsv273 See this version in full on ClinicalTrials.gov ↗
  5. Minor 2 versions Re-verified since Apr 3, 2026, no change to tracked fieldsv271-v272
Show 37 earlier versionsHide 37 earlier versions
  1. Minor Secondary endpoints shortened, about 18 wordsv270 See this version in full on ClinicalTrials.gov ↗
  2. Minor 19 versions Re-verified since Dec 18, 2024, no change to tracked fieldsv251-v269
  3. Minor Eligibility criteria shortened, about 25 words Study description shortened, about 1 wordv250 Show 1 more changeShow less
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Minor 9 versions Re-verified since Jun 30, 2023, no change to tracked fieldsv241-v249
  5. Minor Study Status, Study Description, Eligibilityv240
  6. Minor 2 versions Re-verified since May 20, 2023, no change to tracked fieldsv238-v239
  7. Notable Enrollment target: 11 to 70 Primary completion date: Feb 23, 2022 to Mar 1, 2028 · Trial status: Completed to Recruiting · Completion date: Feb 23, 2022 to Dec 1, 2028 · 1 morev237 Show 4 more changesShow less
    • Primary completion date: Feb 23, 2022 to Mar 1, 2028
    • Trial status: Completed to Recruiting
    • Completion date: Feb 23, 2022 to Dec 1, 2028
    • Site details revised
  8. Minor Re-verified, no change to tracked fieldsv236
  9. Minor Trial status: Recruiting to Completed Enrollment target: estimated 20 to confirmed 11 · Primary completion date changed from estimate of Nov 30, 2022 to Feb 23, 2022 · Study completion date changed from estimate of Dec 31, 2022 to Feb 23, 2022v235 Show 3 more changesShow less
    • Enrollment target: estimated 20 to confirmed 11
    • Primary completion date changed from estimate of Nov 30, 2022 to Feb 23, 2022
    • Study completion date changed from estimate of Dec 31, 2022 to Feb 23, 2022
  10. Notable Primary completion date: Nov 30, 2021 to Nov 30, 2022 Completion date: Dec 31, 2021 to Dec 31, 2022v234 Show 1 more changeShow less
    • Completion date: Dec 31, 2021 to Dec 31, 2022
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tumors of the pituitary gland comprise up to 20% of all brain tumors. The central location and the small size of the pituitary gland make the management of tumors particularly challenging. Transsphenoidal surgery (TSS) to resect pituitary tumors is highly successful at achieving complete cure for functional pituitary adenomas. It is most successful when such adenomas can be localized by preoperative MRI of the pituitary. However, in some instances, small functional tumors cannot be visualized. In the case of Cushing s disease (CD), such non-visualization may be as high as 50%. The success of transsphenoidal surgery is substantially reduced in patients with negative MRI, as some of the adenomas that cause CD are so small that they are difficult to find during surgical exploration of the pituitary. Surgical success is also diminished when tumors invade the walls of the cavernous sinus. MRI of the pituitary lacks imaging resolution to detect such invasion and so the surgeon cannot perform a complete resection with surgery based on the preoperative MRI. Signal to noise ratio (SNR) is the primary constraint on achieving high quality high resolution MRI images. SNR can be improved by longer scan times or by increasing the field strength of the MRI magnet. SNR is proportional to the square of imaging time, however, long imaging times are not clinically feasible. SNR is linearly proportional to field strength, however, replacing MRI magnets is cost prohibitive. Another strong determinant of SNR is the proximity of the MRI receiver coil to the tissue being imaged. Placement of a coil in close proximity to the structure of interest dramatically increases SNR, often as much as 10-fold. Clinically this is routinely put into practice for superficial body parts, such as the temporomandibular joints, in which small coils are placed directly over the joints to achieve rapid high-resolution imaging. For deep structures, the use of superficial coils is of no benefit. This has led to the development of endocavitary coils, such as the endorectal coil used to image the prostate gland. Such coils are now in routine clinical use here at the NIH and elsewhere. During routine TSS, the surgical approach to the pituitary provides a route for placement of imaging tools, such as handheld ultrasound and Doppler probes in close proximity to the gland. Extending this model to MRI imaging, we realized that an endocavitary surface coil within the sphenoid sinus will allow for a marked improvement in SNR for imaging the sella. To this end, we have developed an endosphenoidal coil (ESC), demonstrated its MRI safety, and performed preliminary studies in cadaver heads to determine that the ESC can be placed through the transsphenoidal approach. Placement of ESC needs no modification in the surgical TSS approach to the pituitary gland. The goal of this protocol is to examine the safety and feasibility of ESC placement and imaging during TSS.
Trial Details
NCT Number NCT03678389
Lead Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Pituitary Neoplasm
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov